They showed that the outcomes were slightly less than in the D-E group in AFFIRM (50% PSA decrease: 54%, the median PFS: 8.3 months), revealing the heterogeneity of prostate cancer in terms of AR signaling addiction and drug resistance. The gene discussed is AR; the disease is prostate cancer.